company background image

Eurocine Vaccines NGM:EUCI Stock Report

Last Price


Market Cap







03 Dec, 2022


Company Financials
EUCI fundamental analysis
Snowflake Score
Future Growth0/6
Past Performance0/6
Financial Health6/6

EUCI Stock Overview

Eurocine Vaccines AB (publ) engages in the development of vaccines in Sweden.

Eurocine Vaccines AB (publ) Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Eurocine Vaccines
Historical stock prices
Current Share Pricekr0.84
52 Week Highkr3.80
52 Week Lowkr0.74
1 Month Change2.44%
3 Month Change-42.07%
1 Year Change-77.48%
3 Year Change-91.34%
5 Year Change-99.63%
Change since IPO-99.86%

Recent News & Updates

Recent updates

Shareholder Returns

EUCISE BiotechsSE Market

Return vs Industry: EUCI underperformed the Swedish Biotechs industry which returned -16% over the past year.

Return vs Market: EUCI underperformed the Swedish Market which returned -21.3% over the past year.

Price Volatility

Is EUCI's price volatile compared to industry and market?
EUCI volatility
EUCI Average Weekly Movement13.9%
Biotechs Industry Average Movement8.2%
Market Average Movement7.3%
10% most volatile stocks in SE Market12.4%
10% least volatile stocks in SE Market4.5%

Stable Share Price: EUCI is more volatile than 90% of Swedish stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: EUCI's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of Swedish stocks.

About the Company

19994Hans Arwidsson

Eurocine Vaccines AB (publ) engages in the development of vaccines in Sweden. It has a research and collaboration agreement with Spixia Biotechnology AB to develop, manufacture, and commercialize chlamydia vaccine candidates. The company was incorporated in 1999 and is based in Solna, Sweden.

Eurocine Vaccines AB (publ) Fundamentals Summary

How do Eurocine Vaccines's earnings and revenue compare to its market cap?
EUCI fundamental statistics
Market Capkr23.35m
Earnings (TTM)-kr20.15m
Revenue (TTM)n/a


P/S Ratio


P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
EUCI income statement (TTM)
Cost of Revenuekr0
Gross Profitkr0
Other Expenseskr20.15m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date


Earnings per share (EPS)-0.73
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0.0%

How did EUCI perform over the long term?

See historical performance and comparison